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Objective: Although some investigations have shown a relationship between nonalcoholic
fatty liver disease (NAFLD) and cardiovascular diseases, there are few studies analyzing the
relationship between NAFLD and coronary artery disease (CAD). The aim of this article was
to review the relationship between NAFLD and CAD and the methods of diagnosis used to
assess such relationship.
Methods: A review was performed using search engines of indexed scientiﬁc material,
including MEDLINE (by PubMed), Web of Science, IBECS, and LILACS, to identify articles
published in Portuguese, English, and Spanish until August, 2012. The studies were eligible
if they included the following data: place and year of publication, prevalence and methods
used to diagnose NAFLD (ultrasound, computed tomography, nuclear magnetic resonance,
or biopsy) and CAD (coronary angiography, or computed tomography), and the exclusion of
patients due to alcohol consumption greater than 20g/day.
Results: Ten articles were selected, most of which were cross-sectional studies. The studies
mostly observed the association between NAFLD and the presence and severity of CAD.
Conclusion: The analysis of the review showed that evaluating the existence of NAFLD in
patientswith CAD from its subclinical formup to the symptomatic clinical form is important
due to the higher risk of acute myocardial infarction and consequent increase of mortality.
© 2013 Elsevier Editora Ltda.
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Associac¸ão entre doenc¸a hepática gordurosa não-alcoólica e doenc¸a
arterial coronariana
Palavras-chave:
Doenc¸a hepática gordurosa
Doenc¸as cardiovasculares
Doenc¸a hepática gordurosa não
alcoólica
Doenc¸a arterial coronariana
r e s u m o
Objetivo: Embora algumas investigac¸ões demonstrem uma associac¸ão entre a doenc¸a hep-
ática gordurosa não-alcoólica (DHGNA) e doenc¸as cardiovasculares, existempoucos estudos
analisando a relac¸ão entre DHGNA e doenc¸a arterial coronariana (DAC). O objetivo deste
artigo foi realizar uma revisão sobre a associac¸ão entre DHGNA e CAD e os métodos diag-
nósticos usados para avaliar esta associac¸ão.
Métodos: Foi realizada uma revisão da literatura utilizando métodos de busca de material
cientíﬁco indexado, incluindoMEDLINE (atravésdoPubMed),Webof Science, IBECSe LILACS,
para identiﬁcar artigos publicados em português, inglês e espanhol até agosto de 2012. Os
estudos eramelegíveis se incluíamos seguintes dados: local e anodepublicac¸ão, prevalência
e os métodos utilizados para o diagnóstico da DHGNA (ultrassonograﬁa, tomograﬁa com-
putadorizada, ressonância nuclear magnética ou biópsia) e DAC (angiograﬁa coronária ou
tomograﬁa computadorizada), e a exclusão de pacientes com consumo de álcool maior do
que 20g/dia.
Resultados: Dez artigos foram selecionados, predominando os estudos de corte transversal.
Na maioria dos estudos foi observada a associac¸ão entre DHGNA e a presenc¸a e gravidade
da DAC.
Conclusão: A análise da revisão mostra que é importante avaliar a existência de DHGNA em
pacientes com DAC desde sua forma subclínica até a forma clínica sintomática, devido ao
maior risco de infarto agudo do miocárdio e consequente aumento da mortalidade.
© 2013 Elsevier Editora Ltda.
Introduction
Some investigations have shown a relationship between
nonalcoholic fatty liver disease (NAFLD) and cardiovascular
diseases (CVDs),1–3 with the latter being one of the main
causes of morbidity and mortality in these patients. Although
fatty liver is related to factors (such as dyslipidemia, cen-
tral obesity, diabetes, and metabolic syndrome [MS]) that may
cause CVDs including coronary artery disease (CAD), there are
few studies analyzing the relationship between NAFLD and
CAD, and they present controversial results.
Different methods can be applied to diagnose NAFLD and
CAD. NAFLD can be diagnosed by ultrasound (US), computed
tomography (CT), nuclearmagnetic resonance (NMR), and liver
biopsy. A recent meta-analysis showed that US has a sen-
sitivity from 73.3% to 90.5% and a speciﬁcity from 69.6% to
85.2%. CT has a sensitivity from 46.1% to 72% and a speci-
ﬁcity from 88.1% to 94.6%, but its cost is higher. NMR has a
sensitivity from 82.0% to 97.4% and a speciﬁcity from 76.1%
to 95.3%, and as a noninvasive technique, NMR is good at
diagnosing, especially cases of steatosis < 25%.4 However, due
to its high cost, NMR is not available to most patients. Liver
biopsy is considered the gold standard for diagnosing steato-
sis, but it is an invasive method that may cause bleeding. US
is relatively precise for the diagnosis of NAFLD; and since it is
low-cost, risk-free, and widely available, it has been the most
used method.
Although angiography is the gold standard exam for CAD
diagnosis, the coronary calciﬁcation score identiﬁed by mul-
tislice computed tomography (MSCT) has been proposed as
a potential method to improve the risk discrimination with-
out invasive intervention, because it visualizes not only the
coronary artery stenosis but also the characteristics of the
plaque.5 Thus, thismethod canbeused todiagnose subclinical
CAD.
The aim of this article was to review the relationship
between NAFLD and CAD and the methods of diagnosis used
to assess their relationship.
Methods
A review was performed using bibliographic databases MED-
LINE (by PubMed), Web of Science, IBECS and LILACS, to
identify articles published in Portuguese, English, and Span-
ish until August, 2012. The references of the articles were
also surveyed and retrieved manually to ﬁnd additional
published investigations. During the search, the following
strategy were used in PubMed: (Fatty Liver [MeSH] OR “Non-
alcoholic Fatty Liver Disease”[Supplementary Concept] OR
“Non-alcoholic Fatty Liver Disease”[All Fields] OR “nonalco-
holic fatty liver disease”[All Fields] OR Steatohepatitis OR
steatosis OR NASH OR NAFLD OR (fatty liver AND (non-
alcoholic OR non-alcoholic))AND “coronary disease”[MeSH
Terms] OR (“coronary”[All Fields] AND “disease”[All Fields]) OR
“coronary disease”[All Fields] OR (“coronary”[All Fields] AND
“artery”[All Fields] AND “disease”[All Fields]) OR “coronary
artery disease”[All Fields] OR “coronary artery disease”[MeSH
Terms]). Similar terms were used in other databases. From
each investigation, the speciﬁed protocols were observed,
including the place and year of publication, CAD diagnosis
at the beginning of the investigation, inclusion and exclusion
criteria, criteria for the diagnosis of NAFLD and CAD, maxi-
mum alcohol consumption, NAFLD and CAD prevalence, and
the risk factors involved in the association between NAFLD
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and CAD. The studies were eligible if they had included the
following data: place and year of publication, prevalence and
methods used to diagnose NAFLD (US, CT, NMR, or biopsy)
and CAD (angiography or tomography), exclusion of patients
due to alcohol consumption higher than 20g/day, and other
causes of fatty liver.
Results
Nineteen articles involving the relationship of CADandNAFLD
or steatosis were identiﬁed, and nine were excluded: three6–8
for not fulﬁlling the NAFLD criteria, ﬁve for using other meth-
ods to diagnose CAD,9–13 and one for not citing the diagnostic
method for CAD.14
However, a global interpretation of the investigations
selected (Table 1) was not allowed because they differ with
respect to the design of the study, the size and selected sam-
ples, inclusion and exclusion criteria of patient in each study
(Table 2), methods used to diagnose NAFLD and CAD, and the
confounding factors included in theanalysis. Thus, to evaluate
the association of NAFLD and CAD, the studies were grouped
according to the method used for CAD diagnosis.
Analysis of the selected articles
Type of study
The articles selected had different methods. The major-
ity were characterized as prospective cross-sectional
studies15,19,22 there was also one case-control study,20 two
retrospective cross-sectional studies,21,24 and a prospective
cohort study.23
Locale of the studies and sample size
Nine of the selected studies involved research with Asian
patients. The samples varied from 6120 to 4,023 patients.24
In the investigations using the prospective cross-sectional
model,15–19,22 a total of 2,585 patients were evaluated (Table 1).
Inclusion criteria used for the selection of samples
The studies used the following inclusion criteria: clinical
suspicion of CAD;15,16,18 clinical suspicion of CAD in hospi-
talized patients;22 MS;17 evaluation of risk factors for CVD
and cancer;19 low-intermediate risk for CAD and the pres-
ence of NAFLD without any other hepatobiliary disease;20 the
ﬁrst coronary angiography (CAG);15 check-up for hepatobili-
ary disease and CAD in asymptomatic individuals;21 adults
who received health evaluation24 and age ≥ 18 years21,23 who
underwent CAG.23
Exclusion criteria
There were varied criteria (Table 2) and most investigations
listed only alcohol consumption > 20g/day and the presence
of other liver diseases as common exclusion criteria.
Studies with CAD diagnosis by MSCT
Five investigations assessed CAD by MSCT,16,19–21,24 but
the CAD criteria varied among the investigations. Most of
these studies19,21,24 evaluated the coronary artery calcium
(CAC) score. Two of these investigations21,24 quantiﬁed the
total calcium score according to a scoring system pro-
posed by Agatston et al.25 In two articles,19,21 a CAC score
> 100 was considered to indicate a moderate-high risk
of CAD. In another,24 CAC presence (CAC > 0) was con-
sidered as evidence of calciﬁcation. Two studies analyzed
the characteristics of coronary lesions in MSCT: Akabame
et al.16 classiﬁed the lesionsof coronary arteries as calciﬁed
plaques, non-calciﬁedplaques, low-density plaques, and pos-
itive remodeling vessels, and they observed that all major
arteries had a diameter > 2.0mm using enhanced images.
The lipid pool was deﬁned as having a plaque density of <
60 Hounsﬁeld units (HU), and positive remodeling as having a
remodeling index (RI) > 1.1. A calciﬁed plaque was considered
severe if > 180 HU, and as mild if < 180 HU. Assy et al.20 used
the degree of stenosis of the coronary artery (> 50%) as the
CAD criterion. The plaques were classiﬁed as calciﬁed or non-
calciﬁed on a segmental basis according to plaque features,
including volume, attenuation, and calciﬁcation pattern. A
calciﬁed lesion was deﬁned as a minimum of two pixels (area,
0.52mm2) with a minimum attenuation of 130 HU.
Methods and diagnostic criteria of NAFLD: In two of these
studies, steatosis was diagnosed by CT16,20. In the study by
Akabame et al.,16 hepatic and splenic attenuation values were
measured on non-contrast CT scans using 16 circular region-
of-interest (ROI) cursors in the liver and four in the spleen. The
calculation of the relationship between the liver and spleen
was made by the division between the average value of the
liver attenuation (16 points) and the average value of the
splenic attenuation (4 points). The cut-off value for the liver
to spleen ratio to diagnose NAFLD was deﬁned as < 1.1. Assy
et al.20 deﬁned hepatic steatosis as the result of an attenua-
tion of ≥ -10 HU (calculated as the liver attenuation minus the
spleen attenuation).
Two studies used US for diagnosis of steatosis. In the study
by Jung et al.,19 subjects were diagnosed with steatosis if
at least two of the following three ﬁndings were present:
increased liver echogenicity, deep attenuation, and vascular
blurring. In Kim et al.24 steatosis diagnosiswasmade based on
ultrasound feature characteristics consisting of “bright liver”
and evident contrast between hepatic and renal parenchyma,
vessel blurring, focal sparing, and narrowing of the lumen of
the hepatic veins.
One study21 diagnosed steatosis using US (218 patients) or
CT (77 patients). In CT the following parameters were used:
a liver attenuation lower than the spleen attenuation, pro-
nounced contrast attenuation between the liver and spleen
with blurred intrahepatic vessels, or markedly reduced atten-
uation of the liver with evident contrast between the liver
and the intrahepatic vessels. In patients that had the US
exam, the following parameters were considered: a diffuse
increase in liver echogenicity with clear contrast between
the liver and kidney, liver echogenicity diffusely increased
with undeﬁned intrahepatic vessels or diaphragm, or bright
liver echogenicity with little penetration in the posterior
rev assoc med bras . 2013;59(3):290–297 293
Table 1 – Selected studies about the association of CAD and NAFLD.
Author Locale year N Population CAD prevalence NAFLD prevalence CAD and NAFLD association
Arslan et al.15 Turkey 2007 92 Suspicion
of CAD
43 (46.7%) 65 (70.7%) NAFLD is predictor of CAD (OR:
6.73; 95% CI: 1.14-39.61; p=
0.035)
Akabame et al.16 Japan 2008 298 Suspicion
of CAD
Remodeling
lesions: 56
(18.8%); lipid core
plaques: 50
(16.8%); calciﬁed
plaque: 165
(55.4%); coronary
lumen
narrowing: 165
(55.4%)
60 (20.1%) In NAFLD patients: Remodeling
lesions: 19/60 (31.7%), p = 0.01;
lipid core plaques: 17/60
(28.3%), p= 0.01; calciﬁed
plaque: 36/60 (60.0%), p = 0.47;
coronary lumen narrowing:
47/60 (78.3%), p = 0.47
Alper et al.17 Turkey 2008 80 MS (ATP III) +
suspected CAD
63 (78.8%) 43 (53.8%) NAFLD patients had higher
vessel (2.5 ± 0.9 vs. 1.1± 1.0)
and CAD severity scores
(90.0± 40.0 vs 36.4±28.9), than
patients without NAFLD
(p<0.0001)
Ac¸ikel et al.18 Turkey 2009 355 Suspicion
of CAD
250 (70.4%);
Gensini score:
≤ 36: 178 (50.1%);
>36: 177 (49.9%)
Fatty liver: 215
(60.5%); fatty liver
grades 2-3: 115
(32.4%)
Fatty liver grades 2-3 and CAD:
93/115 (80.9%), p = 0.003; fatty
liver grades 2-3 and Gensini
score>36: 67/115 (58.3%),
p = 0.041
Jung et al.19 Korea 2010 1,218 Subject
submitted to
evaluation of risk
factors for CVD
and cancer
CCS >100: 110
(9.0%)
514 (42.2%) Steatosis and ALT > 30 U/L
predict CCS > 100 (OR: 2.12; 95%
CI: 1.08-4.20; p<0.05), but not
steatosis alone (OR: 1.24; 95%
CI: 0.68-2.26)
Assy et al.20 Israel 2010 61 Low or
intermediate risk
of CAD + fatty
liver or healthy
Cases: 11 (38%)
Controls: 4 (14%)
Cases: 29 NAFLD vs. controls:
non-obstructive lesions: 38%
vs. 14%; Obstructive lesions:
10% vs. 14%. Fatty liver is
predictor of coronary
atherosclerosis (OR: 2.0; 95% CI:
1-4; p < 0.04)
Chen et al.21 Taiwan 2010 295 Asymptomatic
adults who
received a
check-up
CAC score: 0: 179
(60.7%); >100: 38
(12.9%)
121 (41%) NAFLD was an independent
factor that increased the risk of
CAC >100: 23/38 (60.5%); (OR:
2.462; 95% CI: 1.065-5.691; p =
0.035)
Sun and Lu22 China 2011 542 High suspicion
of CAD in
hospitalized
patients
Signiﬁcant
stenosis (≥ 70%):
382 (70.5%); mild
or moderate
injury: 136
(25.1%)
248 (45.7%) Prevalence of NAFLD was
associated with signiﬁcant
CAD: 222/382 (58.1%); (OR:
7.585; 95% CI: 4.617-12.461; p <
0.0001)
Wong et al.23 China 2011 612 Aged ≥ 18 years
who underwent
CAG
465 (76%) 356 (58.2%) Fatty liver was associated with
CAD: 301/465 (64.7%); (OR: 2.31;
95% CI: 1.46-3.64; p < 0.001); the
association was independent
of other metabolic factors
Kim et al.24 Korea 2012 4,023 Adults who
visited health
screening
centers for a
health evaluation
(including CAC)
CAC score > 0:
1,286 (32%)
1,617 (40.2%) NAFLD was associated with
CAC > 0: 649/1,617 (40.1%); (OR:
1.35; 95% CI: 1.15-1.59; p <
0.001)
ALT, alanine aminotransferase; ATP, Adult Treatment Panel; CAC, coronary artery calcium; CAD, coronary artery disease; CAG, coronary angiog-
raphy; CCS, coronary calcium score; CI, conﬁdence interval, CVD, cardiovascular disease; MS, metabolic syndrome; NAFLD, nonalcoholic fatty
liver disease; OR, odds ratio.
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Table 2 – Exclusion criteria used in the selected studies.
Exclusion criteria Arslan
et al.15
Akabam
et al.16
Alper
et al.17
Ac¸ikel
et al.18
Jung
et al.19
Assy
et al.20
Chen
et al.21
Sun and
Lu22
Wong
et al.23
Kim
et al.24
CAD documented in CAG 
Previous CAD  
AMI   
History of CVD 
Coronary bypass grafting 
Prior percutaneous revascularization   
Acute coronary syndrome     
Alcohol consumption(>20g/day)          
Use of drugs that induce steatosis       
Hepatitis B and/or C        
History of liver diseases known       
Systemic diseases that cause steatosis  
Pregnancy 
Congestive heart failure    
Severe pulmonary disease  
Cor pulmonale 
Renal insufﬁciency    
Active infection(chronic or acute) 
Surgery for weight reduction 
Cancer   
Positive serology for HIV and syphilis 
Severe obesity(BMI>35) 
DM2 
Drugs that improve NAFLD 
History of recent acute disease 
History of Cerebrovascular or IHD  
Typical chest pain 
Speciﬁc exclusion criteria for cardiac CT 
Incomplete test  
Contraindications to coronary angiogram 
Antinuclear antibody title >1/160 
History of heart attack 
NOTE: AMI, acute myocardial infarction, BMI, body mass index; DM2, diabetes mellitus type 2; CAD, coronary artery disease; CAG, coronary
angiography; CVD, cardiovascular disease; CT, computed tomography;HIV,Human immunodeﬁciency virus; IHD, Ischemic heart disease; NAFLD,
nonalcoholic fatty liver disease.
segment and the intrahepatic vessels or invisibility of the
diaphragm.
Regarding the prevalences of CAD and NAFLD, in the inves-
tigation that evaluated the total calcium score (CAC), 9% to
12.9% of the individuals had a moderate-high risk of CAD (CAC
>100),while theNAFLDprevalence ranged from20.1% to 42.2%
(Table 1).
Regarding the relationship between CAD and NAFLD, in
those investigations that used MSCT to diagnose CAD, Chen
et al.21 observed a prevalence of NAFLD of 41% (121/295), while
a moderate-high risk of CAD (CAC > 100) was observed in
12.9% (38/295). The prevalence of NAFLD increased as the CAC
score increased (p = 0.003). The results indicated that NAFLD is
related to amoderate-high risk of coronary artery disease (CAC
>100), but NAFLD is not guaranteed to be an independent risk
factor or an epiphenomenon of CAD. In Jung et al.,19 hepatic
steatosiswas found in 42.2% (514/1,218), and coronary calcium
score (CCS) > 100withmoderate-high risk of CVDwas found in
9% (110/1,218) of subjects. An associationwas observed among
the simultaneous presence of steatosis and elevated alanine
aminotransferase (odds ratio [OR] = 2.12; 95% CI: 1.08-4.20; p
< 0.05) and CSS >100, but not with steatosis alone (OR = 1.24;
95% CI: 0.68-2.26). In the study by Kim et al.,24 the presence of
NAFLD was 40.2% (1,617/4,023) and that of CAC > 0 was 32%
(1,286/4,023). In the univariate analysis, the presence of CAC
(score > 0) was signiﬁcantly associatedwithNAFLD. Increasing
CAC scores (0, < 10, 10-100, ≥ 100) were associated with higher
prevalence of NAFLD (OR, 1.84; 95% CI: 1.61-2.10; p < 0.001).
Akabame et al.16 observed the existence of a relationship
between NAFLD and the presence of remodeling lesions (OR
= 2.41; 95% CI: 1.24-4.67; p = 0.0009) and lesions with a lipid
core (OR = 2.29; 95% CI: 1.15-4.56; p = 0.0018), but they did
not observe a correlation with calciﬁed plaques or luminal
stenosis. Assy et al.20 found relationship of NAFLD with a
higher prevalence of calciﬁed and non-calciﬁed plaques and
nonstenotic lesions (38% vs. 14%). Although the presence of
obstructive lesions was more frequent in the controls than
in the patients with NAFLD (14% vs. 10%), the multivariate
analysis showed the association of NAFLD with more severe
coronary atherosclerosis.
Studies with CAD diagnosis by CAG
Five studies assessed CAD through angiography. Once again,
the CAD criteria were different. Three studies deﬁned CAD as
the presence of at least 50% stenosis in at least one major
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coronary artery.15,22,23 Two studies17,22 assessed CAD severity
by the number of vessels affected (vessel score), the degree
of coronary artery stenosis, and by use of the Gensini sever-
ity score.26 The vessel scores ranged from 0 to 3, depending
on the vessels involved. Signiﬁcant stenosis was deﬁned as
a reduction of 70% or greater in the luminal diameter in any
view comparedwith the nearest normal segment. The Gensini
score considers the number of vessels affected, the impor-
tance
of these vessels, the degree of stenosis, and its localiza-
tion in the artery. The cut-off was set as the average value
of Gensini score = 36. The patients were divided into two
groups, those with a Gensini score ≤ 36 points (absent or
mild coronary atherosclerosis) and those with a Gensini score
>36 points (medium to severe coronary atherosclerosis). One
study18 considered CAD if the stenosis was ≥ 50% in the
epicardial coronary arteries or theirmajor branches. In this
investigation, to assess the severity of the coronary atheroscle-
rosis, a modiﬁed Gensini score and the number of vessels
affected (one, two, or three vessels) were used.
Regarding the methods and diagnostic criteria of NAFLD,
four studies used US for NAFLD15,17,18,23 diagnosis. Arslan
et al.15 deﬁned the presence of hepatic steatosis as the dif-
fuse increase in the echogenicity of the liver compared with
the kidney according to the conventional criteria. In Ac¸ikel
et al.,18 the right kidney echogenicity was used to determine
the echogenicity of the hepatic parenchyma, and the liver
was considered normal if it presented echogenicity equal to
that of the kidney (degree 0). Fatty inﬁltration of the liver was
described in three levels: mild (degree 1), when there was a
minimum diffuse increase in the hepatic echogenicity, con-
tours of the diaphragm and intrahepatic vessels with normal
appearance; average (degree 2), when there was a moderate
diffuse increase in thehepatic echogenicity anda slight deteri-
oration in the image of the vessels of the liver anddiaphragm;
and severe (degree 3), when there was an apparent increase in
the echogenicity. The posterior segment of the right lobe of the
liver was difﬁcult to visualize, and the structure of the intra-
hepatic vessels and contours of the diaphragm were smeared
or not viewed.
Alper et al.17 described theUS criteria to diagnose steatosis,
including thehyperechoic appearanceof the liver parenchyma
with ﬁne, tightly packed echoes and posterior beam atten-
uation. Steatosis was classiﬁed as mild, moderate, or severe
when using the following parameters: normal liver – a nor-
mal hepatic echotexture and normal beam attenuation; mild
hepatic steatosis –presence of a minimum increase in the
echogenicity of the liver parenchyma, with a slight decrease
in the deﬁnition of the portal vein walls, and minimal or
no posterior beam attenuation; severe steatosis – a grossly
increased hepatic parenchyma echotexture, allowing only for
the visualization of the main portal vein walls and a strikingly
increased posterior beam attenuation; moderate steatosis –
the characteristics of these parameters (hepatic echogenicity,
portal venous deﬁnition, and beam attenuation) fall between
mild and severe. In the case of a confounding coexistence,
the grade was assigned according to the most predominantly
abnormal ﬁnding. The study by Wong et al.23 was based on
ultrasonographic features of diffusely increased liver echo-
genicity greater than that of the kidney or spleen, vascular
blurring, and deep attenuation of the ultrasound signal. In the
study by Sun and Lu,22 NAFLD was investigated by CT. They
used the same criteria as Chen et al.21
CAD and NAFLD prevalence: CAD prevalence by CAG var-
ied from 46.7% to 95.6%. In these patients, NAFLD prevalence
varied from 32.4% to 70.7% (Table 1)
Regarding the relationship between CAD and NAFLD,
Arslan et al.15 found a prevalence of NAFLD of 70.7% (65/92),
while signiﬁcant CAD was observed in 46.7% (43/92) of the
patients. The probability of detecting the presence of CAD was
6.73 times higher in patients with NAFLD than in patients
without it (p = 0.035). The presence of NAFLD was inde-
pendently related to the presence and extent of CAD. Alper
et al.17observed NAFLD and CAD in 53.8% (43/80) and 78.8%
(63/80), respectively, of the patients with MS. Patients with
NAFLD had signiﬁcantly higher scores for affected vessels
(2.5 ± 0.9 vs. 1.0 ± 1.0) and for the severity of CAD as evaluated
by the Gensini score (90.2 ± 40.0 vs. 36.4 ± 28.9) than patients
without NAFLD (p < 0.001). The presence of NAFLD, the degree
of NAFLD, and the patient’s age were signiﬁcantly correlated
with the severity score of CAD. Ac¸ikel et al.18 found a preva-
lence of NAFLD of 32.4% (115/355), while CAD was present
in 70.4% (250/355) of the patients. They concluded that the
presence of steatosis in the US and its severity may repre-
sent an independent effect in both the presence and severity
of CAD. Sun and Lu22 showed that the prevalence of CAD was
95.6% (518/542) and signiﬁcant CAD was 70.5% (382/542), while
that of NAFLD was 45.7% (248/542). Patients with NAFLD had
signiﬁcantly higher vessel scores (1.5 ± 0.6 vs. 1.4 ± 08, p =
0.001) and more severe CAD scores. Wong et al.23 found fatty
liver prevalence of 58.2% (356/612) while signiﬁcant CAD was
observed in 76.0% (465/612) of subjects. Their study concluded
that fatty liver is associated with CAD independently of other
metabolic factors. However, fatty liver cannot predict cardio-
vascular mortality and morbidity in patients with established
CAD.
Evaluation of other risk factors
Two studies15,21 evaluated the relationship between CAD and
risk factors, three16,17,20 made a similar evaluation concern-
ing NAFLD, and ﬁve evaluated the risk factors associated with
these two conditions.18,19,22–24
The researchers observed relationships between CAD
and increased age,15,18,19,21–24 male gender,18,21–24 previous
myocardial infarction (MI),18,22 hypertension,19,21,24 body
mass index (BMI),24 waist circumference,24 diabetes mellitus
(DM),18,21,24 smoking,18,19,24 dyslipidemia,18 lower levels of
high-density lipoprotein (HDL) cholesterol,18,23,24 high levels
of low-density lipoprotein (LDL) cholesterol,22 triglycerides24
fasting plasma glucose (FPG),19,21,24 total cholesterol (TC),22
aspartate aminotransferase (AST),18,21,22,24 alanine amino-
transferase (ALT),19,22–24 gamma-glutamyltranspeptidase
(GGT),18,24 and the use of lipid-lowering drugs24 (p < 0.05,
respectively). However, other investigations did not relate
CAD to male gender,15 hypertension,15,18,22 DM,22 smoking
history15,21-23 high levels of LDL cholesterol,15,23 lower levels
of HDL cholesterol,15 TC,18,21 triglycerides,15,18,21,22 ALT,18,21
obesity,18,22 waist circumference,15 MS,18,22 or BMI.15,18,22
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NAFLD was related to age in three studies,19,22,24 but
this relationship was not observed in four others.16,17,20,23
NAFLD was also related to DM,22–24 male gender,23,24
waist circumference,17,20,22–24 smoking,24 obesity,22
hypertension,23,24 MS,22 higher levels of triglycerides,17,20,22–24
ALT,20,24 AST,24 GGT,24 TC24 homeostasis model assess-
ment (HOMA),20 lower HDL-cholesterol levels,17,22–24 and
Gensini score.17,22 There was a relationship with BMI in ﬁve
studies16,17,22–24 but not in a different investigation.20 NAFLD
severity(grades 2-3) was associated with the male gender,
dyslipidemia, BMI, obesity, MS, triglycerides, and Gensini
score (p < 0.05).18
There were no relevant differences between patients
with and without NAFLD regarding male gender16,17,22
smoking16,17,22,23 hypertension,16,17,22 DM,16,20 dyslipidemia16
family history of CAD17,22 biochemical parameters of glu-
cose during fasting,16,17 TC,17,22,23 HDL-cholesterol,20 LDL-
cholesterol,17,20,22 AST,22 and ALT.17,22
Discussion
Due todifferences concerning the selection criteria of the sam-
ples, methods, and parameters for CAD and steatosis in most
of the investigations, it is difﬁcult to compare the results. In
investigations that used MSCT to diagnose CAD, two stud-
ies analyzed the characteristics of coronary plaques and their
association with NAFLD and found different results. While
Assy et al., in a small study, found an association of NAFLD
with coronary stenosis of at least 50%, the results of Akabame
et al. indicate that patients with NAFLD might have a risk
factor for vulnerable plaque rather than coronary stenosis.
This result, therefore, suggested that NAFLD was related to
the initial phase of CAD, but not with CAD severity. These
observations highlighted the importance of evaluating NAFLD
in individuals with subclinical CAD to establish strategies
to prevent the evolution of the disease. The study by Chen
et al.21 identiﬁed a correlation between NAFLD and CAC > 100.
However, in the selection of the 295 participants, 1,391 individ-
uals were excluded. In this study, individuals aged ≥ 18 were
included, and the exams, which are expensive, were paid by
thepatients. Thismayhave caused the selection of individuals
with fewer risk factors and higher socioeconomic class. Jung
et al.19 considered CCS > 100 asmoderate to severe risk of CAD,
and identiﬁed a correlation among steatosis and elevated ala-
nine aminotransferase and CAD. However, their sample only
excluded patients with alcohol intake > 20g/day and positive
virus B and C. They did not exclude other secondary causes
of steatosis such as autoimmune diseases and use of hepa-
totoxic drugs, which may constitute an important bias. Kim
et al. considered CAC values > zero as positive, but most of the
patients have positive values between 0 and 100 and there-
fore, low or very low risk for CAD. It was a retrospective study
involving a large number of subjects conducted in two health
screening centers. Due to the study design, information about
patients may have been affected.
Regarding the studies involving angiography to evaluate
the relationship between NAFLD and CAD, such relationship
may be a consequence of the selection. The studies considered
CAD to be the presence of stenosis ≥ 50%, representing the
existence of moderate to severe obstruction of the coronary
arteries. Nevertheless, these studies do not consider the initial
phases of the disease when obstructions < 50% are observed,
conﬁrming the presence ofmild CAD. Taking into account that
coronary occlusionand myocardial ischemia may frequently
be due to mild or moderate stenosis, the identiﬁcation of such
levels of obstruction in patients with NAFLD might be impor-
tant for the risk stratiﬁcation and therapeutic orientation, in
addition to demonstrating such relationship more reliably. In
the study by Arslan et al., NAFLD was observed in 70.7% of the
patients, while coronary disease was present in only 46.7%,
since only patients submitted to the ﬁrst angiography could
take part, and those individuals with previously diagnosed
CAD were excluded. Wong et al.23 also evaluated the effects
of the presence of NAFLD for outcomes, and found no associ-
ation of NAFLD and cardiovascular mortality in patients with
conﬁrmed CAD. These researchers concluded that NAFLD cor-
relates with incident CAD, but cannot be used as a prognostic
marker in patients with established CAD. In the latter case,
the prognosis may be governed by other factors. Their study
included patients referred for CAG by causes other than CAD.
Some comments can be made concerning the investiga-
tions that used the Gensini score,17,18,22 which was used to
establish the severity criterion because it evaluates lesions
from mild to 100% obstruction. The score is determined
according to the importance of the vessel affected, and has
a cut-off value of 36 (Gensini score ≤ 36 points: absent or mild
coronary atherosclerosis; > 36 points:moderate to severe coro-
nary atherosclerosis). Acikel et al.,18 used the Gensini score
in a different form, and no justiﬁcation for such a modiﬁ-
cation was presented, although the results were similar to
other studies17,22. In the study by Sun and Lu,22 the preva-
lence of CADwas 95.6%,with 70.5% (382/542) of the individuals
presenting signiﬁcant stenosis, taking into account the hos-
pitalization of the patients. In their study, a Gensini score
> 36 was established, indicating moderate to severe coronary
atherosclerosis. However, even in the comparison between
patients with signiﬁcant and non-signiﬁcant CAD, the average
Gensini score (23.2 ± 12.1 vs. 10.1 ± 7.0, p < 0.001) was lower
than the cut-off point. When the relationship of NAFLD with
the CAD severity score was evaluated, the average value was
again lower than the cut-off point, although the average score
was higher in patients with NAFLD compared with patients
without NAFLD (24.5 ± 12.6 vs. 14.9 ± 10.4, p < 0.001).
Finally, all selected studies involved Asian patients, and
this should be noted because they have different epidemio-
logical characteristics, lifestyles, and eating habits compared
with Western individuals. The contribution of these charac-
teristics to the association between CAD and NAFLD should
not be neglected.
Conclusion
The studies reviewed in the present article point to the rele-
vance of evaluating CAD in patients with NAFLD, since it may
prevent higher risk of acute myocardial infarction and conse-
quent increase in mortality. However, there are limitations in
this review: the majority of the studies evaluated were cross-
sectional and have a low level of scientiﬁc evidence. Most of
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the studies were performed in Asian patients, and further tri-
als using other study designs are needed, especially involving
Western patients.
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